Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
Adolescent
Adult
Aged
Aged, 80 and over
Case-Control Studies
Child
Female
Fibrinogen
/ analysis
Humans
Hydrocephalus
/ diagnosis
International Normalized Ratio
/ methods
Intracranial Hemorrhages
/ diagnosis
L-Lactate Dehydrogenase
/ blood
Leukemia, Promyelocytic, Acute
/ blood
Male
Middle Aged
Mortality
Neuroradiography
/ methods
Precision Medicine
/ statistics & numerical data
Predictive Value of Tests
Remission Induction
/ methods
Risk Factors
Tomography, X-Ray Computed
/ methods
Young Adult
acute promyelocytic leukaemia
early death
intracranial haemorrhage
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
26
05
2020
accepted:
09
07
2020
pubmed:
19
8
2020
medline:
31
7
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Acute promyelocytic leukaemia (APL) represents a modern success of precision medicine. However, fatalities occurring within the first 30 days of induction treatment, in particular intracranial haemorrhage (ICH), remain the main causes of death. We studied the clinico-biological characteristics of 13 patients with APL who experienced ICH. Compared to 85 patients without this complication, patients with ICH were older and more frequently had high-risk APL. Moreover, positivity for the 'swirl' sign at neuroradiological imaging and hydrocephalus were predictors of a fatal outcome, together with lower fibrinogen, prolonged international normalized ratio (INR) and higher lactate dehydrogenase levels.
Substances chimiques
Fibrinogen
9001-32-5
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-132Subventions
Organisme : Innovative Medicines Initiative (IMI) 2 project "HARMONY"
ID : 116026
Organisme : AIRC 5x1000 call "Metastatic disease: the key unmet need in oncology" to MYNERVA project
ID : 21267
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020;34:914-8.
Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95:673-80.
Breccia, M & Lo Coco, F. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res. 2014;133(Suppl 2):S112-S116.
Martinez-Cuadron D, Sobas M, Vellenga E, Fernandez I, Sossa C, de Lisa E, et al. PF255 incidence and risk factors for early death among 2421 APL patients: the pethema registry experience. HemaSphere. 2019;3:78-9.
Naymagon L, Moshier E, Tremblay D, Mascarenhas J. Predictors of early hemorrhage in acute promyelocytic leukemia. Leuk Lymphoma. 2019;60:2394-403.
Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88:321-8.
Hou W, Zhang Y, Jin B, Cao W, Lu M, Yan L, et al. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone. Blood Cells Mol Dis. 2019;79:102351.
Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129:1763-7.
Sun J, Zhu J, Zhou D, Zhu L, Yang X, Xie M, et al. Factors affecting early death and survival of patients with acute promyelocytic leukemia treated with ATRA-based therapy regimens. Clin Lymphoma Myeloma Leuk. 2019b;19:e63-e70.
Al-Mufti F, Thabet AM, Singh T, El-Ghanem M, Amuluru K, Gandhi CD. Clinical and radiographic predictors of intracerebral hemorrhage outcome. Interv Neurol. 2018;7:118-36.
Sanz, MA, Lo Coco, F, Martin, G, Avvisati, G, Rayon, C & Barbui, T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-53.
Selariu E, Zia E, Brizzi M, Abul-Kasim K. Swirl sign in intracerebral haemorrhage: definition, prevalence, reliability and prognostic value. BMC Neurol. 2012;12:109.
Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, Choi Y, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35:152-8.
Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis. 2011;3:e2011068.
Mitrovic M, Suvajdzic N, Bogdanovic A, Kurtovic NK, Sretenovic A, Elezovic I, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation >/= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30:478.
Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213-9.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630-43.
Chien N, Varghese C, Green TN, Chan G, Theakston E, Eaddy N, et al. Treatment outcomes of patients with acute promyelocytic leukaemia between 2000 and 2017, a retrospective, single centre experience. Leuk Res. 2020;93:106358.